Association/NN
of/IN
the/DT
X-linked/JJ
Androgen/NN
Receptor/NN
Leu57Gln/NN
Polymorphism/NN
with/IN
Monomelic/JJ
Amyotrophy/NN
./.
====================
Monomelic/JJ
amyotrophy/NN
(/(
MA/NN
)/)
,/,
also/RB
known/VBN
as/IN
Hirayama/JJ
disease/NN
,/,
occurs/VBZ
mainly/RB
in/IN
young/JJ
men/NNS
and/CC
manifests/VBZ
as/IN
weakness/RB
and/CC
wasting/VBG
of/IN
the/DT
muscles/NNS
of/IN
the/DT
distal/JJ
upper/IN
limbs/NNS
./.
====================
Here/RB
,/,
we/PRP
sought/VBD
to/TO
identify/VB
a/DT
genetic/JJ
basis/NN
for/IN
MA/NN
./.
====================
Given/IN
the/DT
predominance/NN
of/IN
MA/NN
in/IN
males/NNS
,/,
we/PRP
focused/VBD
on/IN
candidate/NN
neurological/JJ
disease/NN
genes/NNS
located/JJ
on/IN
the/DT
X/NN
chromosome/NN
,/,
selecting/VBG
two/CD
Xlinked/JJ
candidate/NN
genes/NNS
,/,
androgen/NN
receptor/NN
(/(
AR/NNS
)/)
and/CC
ubiquitinlike/JJ
modifier/NN
activating/VBG
enzyme/NN
1/CD
(/(
UBA1/NN
)/)
./.
====================
Screening/VBG
for/IN
genetic/JJ
variants/NNS
using/VBG
patients/NNS
’/CD
genomic/JJ
DNA/NN
revealed/VBD
three/CD
known/VBN
genetic/JJ
variants/NNS
in/IN
the/DT
coding/VBG
region/NN
of/IN
the/DT
AR/NNS
gene/NN
:/:
one/CD
nonsynonymous/JJ
single-nucleotide/JJ
polymorphism/NN
(/(
SNP/NN
;/:
rs78686797/RB
)/)
encoding/VBG
Leu57Gln/NN
,/,
and/CC
two/CD
variants/NNS
of/IN
polymorphic/JJ
trinucleotide/NN
repeat/NN
segments/NNS
that/DT
encode/VBP
polyglutamine/JJ
(/(
CAG/NN
repeat/NN
;/:
rs5902610/RB
)/)
and/CC
polyglycine/NN
(/(
GGC/NN
repeat/NN
;/:
rs3138869/RB
)/)
tracts/VBZ
./.
====================
Notably/RB
,/,
the/DT
Leu57Gln/NN
polymorphism/NN
was/VBD
found/VBN
in/IN
two/CD
patients/NNS
with/IN
MA/NN
from/IN
24/CD
MA/NN
patients/NNS
,/,
whereas/IN
no/DT
variants/NNS
were/VBD
found/VBN
in/IN
142/CD
healthy/JJ
male/JJ
controls/NNS
./.
====================
However/RB
,/,
the/DT
numbers/NNS
of/IN
CAG/NN
and/CC
GGC/NN
repeats/NNS
in/IN
the/DT
AR/NNS
gene/NN
were/VBD
within/IN
the/DT
normal/JJ
range/NN
./.
====================
These/DT
data/NNS
suggest/VBP
that/IN
the/DT
Leu57Gln/NN
polymorphism/NN
encoded/VBN
by/IN
the/DT
Xlinked/JJ
AR/NNS
gene/NN
may/MD
contribute/VB
to/TO
the/DT
development/NN
of/IN
MA/NN
./.
====================
Keywords/IN
:/:
X-linked/JJ
gene/NN
,/,
androgen/CC
receptor/NN
(/(
AR/NNS
)/)
gene/NN
,/,
monomelic/JJ
amyotrophy/RB
(/(
MA/NN
)/)
,/,
case-control/JJ
studyMonomelic/JJ
amyotrophy/RB
(/(
MA/NN
;/:
MIM/NN
602440/CD
)/)
,/,
also/RB
known/VBN
as/IN
Hirayama/JJ
disease/NN
,/,
is/VBZ
a/DT
rare/JJ
motor/NN
neuron/NN
disease/NN
mainly/RB
afflicting/VBG
young/JJ
males/NNS
that/IN
is/VBZ
characterized/VBN
by/IN
weakness/JJ
and/CC
wasting/VBG
of/IN
the/DT
muscles/NNS
confined/VBN
to/TO
the/DT
hand/NN
and/CC
forearm/IN
,/,
without/IN
sensory/JJ
or/CC
pyramidal/JJ
tract/VBP
involvement/NN
(/(
Hirayama/NNP
et/FW
al./FW
,/,
1987/CD
)/)
./.
====================
It/PRP
follows/VBZ
a/DT
nonprogressive/JJ
course/NN
after/IN
a/DT
few/JJ
years/NNS
of/IN
unilateral/JJ
or/CC
bilateral/JJ
progression/NN
(/(
Misra/NN
et/FW
al./FW
,/,
2006/CD
)/)
./.
====================
MA/NN
was/VBD
first/JJ
reported/VBD
as/IN
juvenile/RB
muscular/JJ
atrophy/NN
of/IN
an/DT
upper/JJ
extremity/NN
in/IN
Japanese/JJ
patients/NNS
(/(
Hirayama/NN
et/FW
al./FW
,/,
1959/CD
)/)
./.
====================
To/TO
date/NN
,/,
most/JJS
studies/NNS
have/VBP
involved/VBN
a/DT
very/RB
limited/JJ
numbers/NNS
of/IN
patients/NNS
and/CC
have/VBP
focused/VBN
on/IN
case/NN
reports/NNS
,/,
mainly/RB
from/IN
Asian/JJ
countries/NNS
such/JJ
as/IN
Japan/JJ
and/CC
India/NN
./.
====================
These/DT
studies/NNS
have/VBP
included/VBN
38/CD
cases/NNS
and/CC
73/CD
cases/NNS
with/IN
MA/NN
in/IN
a/DT
Japanese/JJ
population/NN
(/(
Hirayama/NNP
,/,
1972/CD
;/:
Hirayama/NNP
and/CC
Tokumaru/NNP
,/,
2000/CD
)/)
,/,
a/DT
sibling/JJ
case/NN
in/IN
Turkey/NNP
(/(
Gucuyener/NNP
et/FW
al./FW
,/,
1991/CD
)/)
,/,
44/CD
patients/NNS
and/CC
a/DT
case/NN
from/IN
India/NNP
(/(
GourieDevi/NNP
and/CC
Nalini/NNP
,/,
2003/CD
;/:
Nalini/NNP
et/FW
al./FW
,/,
2004/CD
)/)
,/,
a/DT
sporadic/JJ
case/NN
in/IN
an/DT
Italian/JJ
man/JJ
(/(
Rigamonti/NNP
et/FW
al./FW
,/,
2004/CD
)/)
,/,
a/DT
young/JJ
Swiss/NNP
female/JJ
patient/NN
with/IN
MA/NN
(/(
Jeannet/NNP
et/FW
al./FW
,/,
2005/CD
)/)
,/,
and/CC
15/CD
male/JJ
cases/NNS
from/IN
14/CD
Indian/JJ
families/NNS
(/(
Misra/NNP
et/FW
al./FW
,/,
2005/CD
)/)
./.
====================
Currently/RB
,/,
the/DT
pathophysiology/NN
of/IN
MA/NN
is/VBZ
not/RB
well/RB
understood/VBN
but/CC
various/JJ
possibilities/NNS
have/VBP
been/VBN
considered/VBN
,/,
including/VBG
autoimmune/JJ
and/CC
genetic/JJ
factors/NNS
,/,
and/CC
ischemic/JJ
changes/NNS
of/IN
the/DT
spinal/JJ
cord/NN
induced/VBD
by/IN
neck/NN
flexion/NN
(/(
Nalini/NNS
et/FW
al./FW
,/,
2004/CD
)/)
./.
====================
Rare/RB
familial/JJ
cases/NNS
have/VBP
suggested/VBN
the/DT
possibility/NN
of/IN
either/CC
autosomalrecessive/JJ
or/CC
autosomaldominant/JJ
inheritance/VBP
patterns/NNS
in/IN
different/JJ
families/NNS
(/(
Nalini/NNS
et/FW
al./FW
,/,
2004/CD
;/:
Schlegel/NNP
et/FW
al./FW
,/,
1987/CD
;/:
Sobue/JJ
et/FW
al./FW
,/,
1978/CD
)/)
./.
====================
In/IN
the/DT
few/JJ
previous/JJ
genetic/JJ
association/NN
studies/NNS
,/,
the/DT
role/NN
of/IN
deletions/NNS
in/IN
SMN1/NN
and/CC
SMN2/NN
genes/NNS
was/VBD
excluded/VBN
(/(
Di/NNP
Guglielmo/NN
et/FW
al./FW
,/,
1996/CD
;/:
Gamez/NNP
et/FW
al./FW
,/,
2007/CD
;/:
Misra/NN
et/FW
al./FW
,/,
2005/CD
)/)
./.
====================
In/IN
addition/NN
,/,
abnormal/JJ
expansion/NN
of/IN
CAG/NN
repeats/NNS
of/IN
the/DT
androgen/NN
receptor/NN
gene/NN
has/VBZ
not/RB
been/VBN
found/VBN
in/IN
patients/NNS
with/IN
MA/NN
(/(
Katila/NN
et/FW
al./FW
,/,
2007/CD
)/)
./.
====================
Thus/RB
,/,
the/DT
genetic/JJ
cause/VBP
of/IN
MA/NN
is/VBZ
still/RB
unknown/JJ
./.
====================
However/RB
,/,
the/DT
predominant/JJ
occurrence/NN
of/IN
MA/NN
in/IN
males/NNS
suggests/VBZ
that/IN
gene/NN
(/(
s/NNS
)/)
in/IN
the/DT
X/NN
chromosome/NN
may/MD
play/VB
a/DT
role/NN
in/IN
MA/NN
(/(
Misra/NN
et/FW
al./FW
,/,
2005/CD
)/)
./.
====================
Thus/RB
,/,
in/IN
this/DT
study/NN
,/,
we/PRP
tested/VBD
whether/IN
genetic/JJ
variants/NNS
found/VBN
in/IN
two/CD
Xlinked/JJ
neurological/JJ
candidate/NN
genesandrogen/NN
receptor/NN
(/(
AR/NNS
)/)
and/CC
ubiquitinlike/JJ
modifier/NN
activating/VBG
enzyme/NN
1/CD
(/(
UBA1/NN
)/)
are/VBP
involved/VBN
in/IN
the/DT
development/NN
of/IN
MA/NN
in/IN
Korean/JJ
patients/NNS
./.
====================
For/IN
the/DT
analysis/NN
of/IN
clinical/JJ
characteristics/NNS
of/IN
MA/NN
,/,
clinical/JJ
data/NNS
were/VBD
collected/VBN
from/IN
34/CD
patients/NNS
who/WP
were/VBD
diagnosed/VBN
at/IN
Asan/NN
Medical/JJ
Center/NN
./.
====================
For/IN
the/DT
genetic/JJ
study/NN
,/,
genomic/JJ
DNA/NN
samples/NNS
from/IN
a/DT
total/JJ
of/IN
24/CD
patients/NNS
,/,
including/VBG
22/CD
males/NNS
and/CC
two/CD
females/NNS
,/,
were/VBD
collected/VBN
from/IN
Asan/NN
Medical/JJ
Center/NN
and/CC
Pusan/NN
National/JJ
University/NN
Hospital/JJ
./.
====================
All/DT
patients/NNS
were/VBD
diagnosed/VBN
by/IN
neurologists/NNS
according/VBG
to/TO
the/DT
following/VBG
diagnostic/JJ
criteria/NNS
:/:
(/(
1/LS
)/)
insidious/JJ
onset/RB
between/IN
age/NN
14/CD
and/CC
25/CD
years/NNS
;/:
(/(
ii/LS
)/)
unilateral/JJ
or/CC
asymmetric/JJ
muscle/RB
weakness/RB
and/CC
wasting/VBG
in/IN
the/DT
hand/CC
and/CC
forearm/IN
;/:
(/(
iii/LS
)/)
lack/RB
of/IN
involvement/JJ
of/IN
cranial/JJ
nerves/RB
,/,
pyramidal/JJ
tracts/VBZ
,/,
sphincters/VBZ
and/CC
sensory/JJ
systems/NNS
,/,
and/CC
absence/RB
of/IN
reflex/JJ
changes/NNS
in/IN
upper/IN
extremities/VBZ
;/:
(/(
iv/LS
)/)
nonprogressive/JJ
course/RB
and/CC
spontaneous/JJ
arrest/RB
of/IN
disease/JJ
within/IN
several/JJ
years/NNS
after/IN
onset/RB
;/:
(/(
v/LS
)/)
no/DT
history/JJ
of/IN
toxin/NN
exposure/NN
,/,
poliomyelitis/RB
,/,
or/CC
other/JJ
causes/VBZ
for/IN
clinical/JJ
presentations/NNS
;/:
and/CC
(/(
vi/LS
)/)
normal/JJ
motor/NN
and/CC
sensory/JJ
nerve/RB
conductions/NNS
and/CC
neurogenic/JJ
changes/NNS
confined/VBN
to/TO
C7/NNP
,/,
C8/NNP
,/,
and/CC
T1/NN
myotomes/VBZ
in/IN
electrodiagnostic/JJ
tests/NNS
(/(
Hirayama/NNP
et/FW
al./FW
,/,
1987/CD
;/:
Singh/IN
et/FW
al./FW
,/,
1980/CD
)/)
./.
====================
Control/NN
samples/NNS
with/IN
no/DT
history/JJ
of/IN
disease/NN
were/VBD
obtained/VBN
from/IN
the/DT
Biobank/NN
for/IN
Health/NN
Sciences/NNS
at/IN
the/DT
Center/NN
for/IN
Genome/NN
Sciences/NNS
in/IN
Seoul/JJ
,/,
Korea/NN
./.
====================
The/DT
study/NN
was/VBD
approved/VBN
by/IN
the/DT
Institutional/JJ
Review/NN
Board/JJ
of/IN
Asan/NN
Medical/JJ
Center/NN
,/,
University/JJ
of/IN
Ulsan/NN
College/NN
of/IN
Medicine/NN
,/,
Seoul/JJ
,/,
Korea/NN
./.
====================
All/DT
patients/NNS
or/CC
their/PRP$
parents/NNS
provided/VBD
written/CD
informed/VBN
consent/NN
./.
====================
To/TO
identify/VB
candidate/NN
causal/JJ
variants/NNS
,/,
we/PRP
sequenced/VBD
two/CD
X-linked/JJ
candidate/NN
genes/NNS
(/(
AR/NNS
and/CC
UAB1/NN
)/)
using/VBG
genomic/JJ
DNA/NN
from/IN
nine/CD
patients/NNS
with/IN
MA/NN
and/CC
one/CD
healthy/JJ
control/JJ
subject/JJ
./.
====================
Genomic/JJ
sequences/NNS
of/IN
AR/NNS
and/CC
UAB1/NN
for/IN
sequencing/NN
analysis/NN
were/VBD
obtained/VBN
from/IN
the/DT
GenBank/NN
(/(
http/NN
:/:
//www/JJ
./.
====================
ncbi/nlm/RB
./.
====================
nih/DT
./.
====================
gov//DT
)/)
database/NN
,/,
and/CC
polymerase/NN
chain/NN
reaction/NN
(/(
PCR/NN
)/)
primers/NNS
to/TO
amplify/VB
coding/VBG
regions/NNS
and/CC
promoter/NN
regions/NNS
(/(
500/CD
bp/NN
upstream/RB
from/IN
exon/NN
10/CD
of/IN
the/DT
genes/NNS
)/)
were/VBD
designed/VBN
using/VBG
Primer3/NN
software/RB
(/(
http/NN
:/:
//frodo/JJ
./.
====================
wi/IN
./.
====================
mit/VBP
./.
====================
edu/primer3//RB
)/)
./.
====================
Each/DT
fragment/NN
amplified/VBD
by/IN
PCR/NN
was/VBD
sequenced/VBN
with/IN
an/DT
ABI/NN
Prism/NN
3730/CD
sequencer/NN
(/(
Applied/VBN
Biosystems/NNS
,/,
Foster/NN
City/NN
,/,
CA/NNP
,/,
USA/NN
)/)
./.
====================
DNA/NN
polymorphisms/NNS
were/VBD
identified/VBN
using/VBG
the/DT
PolyPhred/JJ
program/NN
(/(
http/NN
:/:
//droog/NN
./.
====================
gs/NNS
./.
====================
washington/NN
./.
====================
edu/polyphred//RB
)/)
./.
====================
For/IN
the/DT
genetic/JJ
association/NN
study/NN
,/,
candidate/NN
variants/NNS
found/VBN
in/IN
the/DT
AR/NNS
gene/NN
were/VBD
genotyped/VBN
by/IN
resequencing/VBG
using/VBG
all/DT
24/CD
patients/NNS
with/IN
MA/NN
and/CC
142/CD
healthy/JJ
control/JJ
subjects/NNS
./.
====================
Statistical/JJ
analyses/NNS
for/IN
the/DT
casecontrol/NN
study/NN
were/VBD
performed/VBN
using/VBG
SPSS/NN
(/(
version/NN
18/CD
)/)
software/RB
(/(
SPSS/NN
Inc./NNP
,/,
Chicago/JJ
,/,
IL/NN
,/,
USA/NN
)/)
./.
====================
The/DT
association/NN
with/IN
MA/NN
was/VBD
tested/VBN
using/VBG
Fisher/JJ
’/CD
s/NNS
exact/JJ
test/NN
./.
====================
Since/IN
1989/CD
,/,
a/DT
total/JJ
of/IN
34/CD
patients/NNS
,/,
including/VBG
two/CD
females/NNS
,/,
have/VBP
been/VBN
diagnosed/VBN
with/IN
MA/NN
at/IN
Asan/NN
Medical/JJ
Center/NN
./.
====================
The/DT
clinical/JJ
characteristics/NNS
of/IN
MA/NN
in/IN
these/DT
Korean/JJ
patients/NNS
were/VBD
analyzed/VBN
based/VBN
on/IN
clinical/JJ
data/NNS
./.
====================
Similar/JJ
to/TO
previously/RB
reported/VBD
by/IN
another/DT
groups/NNS
,/,
MA/NN
exhibited/VBD
a/DT
predominantly/RB
juvenile/IN
onset/NN
,/,
between/IN
age/NN
15/CD
and/CC
25/CD
(/(
mean/JJ
age/NN
at/IN
disease/NN
onset/NN
,/,
17.65/CD
years/NNS
)/)
,/,
and/CC
mainly/RB
affected/VBN
males/NNS
(/(
Fig/NN
./.
====================
1/CD
)/)
./.
====================
In/IN
27/CD
of/IN
34/CD
patients/NNS
(/(
79.4/CD
%/NN
)/)
,/,
symptom/IN
onset/NN
occurred/VBD
before/IN
20/CD
years/NNS
of/IN
age/NN
./.
====================
There/EX
was/VBD
no/DT
family/NN
history/NN
of/IN
MA/NN
or/CC
other/JJ
neurologic/JJ
disorders/NNS
affecting/VBG
anterior/JJ
horn/NN
cells/NNS
./.
====================
Arm/NN
weakness/RB
started/VBD
unilaterally/RB
in/IN
all/DT
patients/NNS
,/,
but/CC
subsequently/RB
affected/VBN
the/DT
other/JJ
side/JJ
within/IN
1/CD
year/NN
in/IN
five/CD
patients/NNS
(/(
14.7/CD
%/NN
)/)
./.
====================
The/DT
initial/JJ
progression/NN
was/VBD
stabilized/VBN
15/CD
years/NNS
after/IN
onset/NN
./.
====================
The/DT
clinical/JJ
features/NNS
of/IN
MA/NN
bear/JJ
some/DT
resemblance/NN
to/TO
spinal/JJ
muscular/JJ
atrophy/NN
(/(
SMA/NN
)/)
,/,
Kennedy/NN
disease/NN
,/,
and/CC
familial/JJ
amyotrophic/JJ
lateral/JJ
sclerosis/NN
(/(
ALS/NNS
)/)
./.
====================
We/PRP
hypothesized/VBD
that/IN
a/DT
different/JJ
mutation/NN
in/IN
that/DT
same/JJ
gene/NN
that/WDT
causes/VBZ
these/DT
neurological/JJ
diseases/NNS
(/(
i./FW
e./FW
,/,
allelic/JJ
heterogeneity/NN
)/)
could/MD
result/VB
in/IN
a/DT
slightly/RB
different/JJ
phenotype/NN
in/IN
MA/NN
./.
====================
In/IN
order/NN
to/TO
test/VB
our/PRP$
hypothesis/NN
,/,
we/PRP
initially/RB
selected/VBN
20/CD
candidate/NN
genes/NNS
(/(
ALS2/NN
,/,
ANG/NN
,/,
AR/NNS
,/,
BSCL2/NN
,/,
DCTN1/NN
,/,
FIG4/NN
,/,
FUS/NNP
,/,
GARS/NN
,/,
HMN7B/NN
,/,
HSPB8/NN
,/,
IGHMBP2/NN
,/,
NEFH/NN
,/,
PRPH/NN
,/,
PLEKHG5/NN
,/,
SETX/NN
,/,
SMN1/NNP
,/,
SMN2/NN
,/,
SOD1/NN
,/,
TARFBP/NN
,/,
UBA1/NN
,/,
VAPB/NN
)/)
that/IN
are/VBP
involved/VBN
in/IN
either/CC
SMA/NN
,/,
Kennedy/NN
disease/NN
or/CC
familial/JJ
ALS/NNS
./.
====================
In/IN
addition/NN
,/,
94/CD
%/NN
of/IN
our/PRP$
Korean/NN
MA/NN
patients/NNS
were/VBD
males/NNS
,/,
suggesting/VBG
that/IN
genetic/JJ
defects/NNS
on/IN
the/DT
X/NN
chromosome/NN
might/MD
play/VB
a/DT
crucial/JJ
role/NN
in/IN
MA/NN
./.
====================
Thus/RB
,/,
among/IN
the/DT
initially/RB
selected/VBN
20/CD
neurological/JJ
candidate/NN
genes/NNS
,/,
we/PRP
focused/VBD
on/IN
the/DT
Xlinked/JJ
genes/NNS
,/,
AR/NNS
and/CC
UBA1/NN
./.
====================
After/IN
sequencing/NN
of/IN
promoter/NN
regions/NNS
and/CC
coding/VBG
regions/NNS
in/IN
the/DT
AR/NNS
and/CC
UBA1/NN
genes/NNS
using/VBG
genomic/JJ
DNA/NN
from/IN
nine/CD
MA/NN
patients/NNS
and/CC
one/CD
normal/JJ
control/JJ
,/,
we/PRP
found/VBD
a/DT
total/JJ
of/IN
seven/CD
genetic/JJ
variants/NNS
,/,
four/CD
in/IN
the/DT
AR/NNS
gene/NN
and/CC
three/CD
in/IN
the/DT
UBA1/NN
gene/NN
(/(
Table/JJ
1/CD
)/)
./.
====================
Notably/RB
,/,
three/CD
AR/NNS
gene/NN
variants/NNS
contained/VBD
substitutions/NNS
located/JJ
in/IN
the/DT
coding/VBG
region/NN
that/IN
altered/JJ
the/DT
amino/NN
acid/NN
sequence/NN
:/:
one/CD
was/VBD
a/DT
nonsynonymous/JJ
singlenucleotide/JJ
polymorphism/NN
(/(
SNP/NN
;/:
rs78686797/RB
)/)
encoding/VBG
Leu57Gln/NN
,/,
and/CC
two/CD
were/VBD
polymorphic/JJ
trinucleotide/NN
repeat/NN
segments/NNS
that/DT
encoded/VBN
polyglutamine/NN
(/(
rs5902610/CD
;/:
CAGrepeat/NN
)/)
and/CC
polyglycine/NN
(/(
rs3138869/CD
;/:
GGCrepeat/NNP
)/)
tracts/VBZ
./.
====================
We/PRP
mainly/RB
focused/VBN
on/IN
these/DT
coding/VBG
polymorphisms/NNS
in/IN
AR/NNS
gene/NN
for/IN
genetic/JJ
association/NN
study/NN
with/IN
MA/NN
./.
====================
Among/IN
24/CD
patients/NNS
with/IN
MA/NN
,/,
two/CD
male/JJ
patients/NNS
possessed/VBD
the/DT
Leu57Gln/NN
polymorphism/NN
,/,
whereas/IN
none/NN
of/IN
the/DT
normal/JJ
controls/NNS
(/(
n=56/CD
)/)
used/VBN
in/IN
an/DT
initial/JJ
casecontrol/NN
study/NN
carried/VBD
this/DT
variant/JJ
(/(
Fig/NN
./.
====================
2/CD
)/)
./.
====================
Furthermore/RB
,/,
this/DT
variant/JJ
was/VBD
not/RB
detected/VBN
even/RB
in/IN
a/DT
larger/RBR
set/NN
of/IN
control/JJ
samples/NNS
(/(
n=142/CD
)/)
,/,
demonstrating/VBG
a/DT
significant/JJ
association/NN
with/IN
MA/NN
(/(
p=0.02/NN
;/:
Fisher/RB
’/CD
s/NNS
exact/JJ
test/NN
;/:
Table/JJ
2/CD
)/)
./.
====================
In/IN
addition/NN
,/,
an/DT
in/FW
silico/NN
prediction/NN
of/IN
the/DT
functionality/NN
of/IN
the/DT
leu57Gln/NN
polymorphism/NN
using/VBG
the/DT
program/NN
PolyPhen/NNP
showed/VBD
the/DT
polymorphism/NN
site/NN
to/TO
be/VB
“/CD
probably/RB
damaging/VBG
”/CD
(/(
Table/JJ
1/CD
)/)
./.
====================
Therefore/RB
,/,
it/PRP
is/VBZ
likely/JJ
that/IN
the/DT
Leu57Gln/NN
polymorphism/NN
is/VBZ
biologically/RB
functional/JJ
,/,
suggesting/VBG
that/IN
it/PRP
may/MD
contribute/VB
to/TO
the/DT
development/NN
of/IN
MA/NN
./.
====================
On/IN
the/DT
other/JJ
hand/NN
,/,
however/RB
,/,
the/DT
numbers/NNS
of/IN
variable/JJ
CAG/NN
repeats/NNS
(/(
rs5902610/CD
)/)
and/CC
GGC/NN
repeats/NNS
(/(
rs3138869/CD
)/)
in/IN
the/DT
AR/NNS
gene/NN
were/VBD
within/IN
the/DT
normal/JJ
range/NN
,/,
and/CC
their/PRP$
frequencies/NNS
were/VBD
very/RB
similar/JJ
to/TO
those/DT
of/IN
healthy/JJ
controls/NNS
(/(
Fig/NN
./.
====================
2/CD
)/)
./.
====================
This/DT
result/NN
indicates/VBZ
that/IN
variation/NN
in/IN
CAG/NN
and/CC
GGC/NN
repeats/NNS
does/VBZ
not/RB
likely/JJ
contribute/VBP
to/TO
the/DT
development/NN
of/IN
MA/NN
./.
====================
MA/NN
is/VBZ
a/DT
very/RB
rare/JJ
neurological/JJ
disease/NN
,/,
making/VBG
genetic/JJ
studies/NNS
very/RB
difficult/JJ
./.
====================
Most/JJS
studies/NNS
conducted/VBD
to/TO
date/NN
have/VBP
included/VBN
a/DT
very/RB
limited/JJ
numbers/NNS
of/IN
patients/NNS
and/CC
have/VBP
focused/VBN
on/IN
case/NN
reports/NNS
./.
====================
Rare/RB
familial/JJ
MA/NN
cases/NNS
have/VBP
suggested/VBN
that/IN
MA/NN
can/MD
be/VB
inherited/VBN
in/IN
a/DT
dominant/JJ
or/CC
recessive/JJ
manner/NN
in/IN
different/JJ
families/NNS
(/(
Nalini/NNS
et/FW
al./FW
,/,
2004/CD
)/)
./.
====================
Moreover/RB
,/,
MA/NN
occurs/VBZ
almost/RB
exclusively/RB
in/IN
male/JJ
patients/NNS
(/(
Misra/NN
et/FW
al./FW
,/,
2005/CD
)/)
,/,
thus/RB
,/,
we/PRP
hypothesized/VBD
that/IN
gene/NN
(/(
s/NNS
)/)
on/IN
the/DT
X/NN
chromosome/NN
may/MD
play/VB
a/DT
crucial/JJ
role/NN
in/IN
MA/NN
./.
====================
In/IN
this/DT
study/NN
,/,
we/PRP
selected/VBD
the/DT
two/CD
Xlinked/JJ
genes/NNS
,/,
AR/NNS
and/CC
UBA1/NN
,/,
from/IN
among/IN
the/DT
candidate/NN
genes/NNS
of/IN
the/DT
similar/JJ
neurological/JJ
diseases/NNS
,/,
SMA/NN
,/,
Kennedy/NN
disease/NN
and/CC
familial/JJ
ALS/NNS
./.
====================
Interestingly/RB
,/,
a/DT
polymorphism/NN
of/IN
the/DT
AR/NNS
gene/NN
encoding/VBG
Leu57Gln/NN
was/VBD
found/VBN
in/IN
two/CD
of/IN
24/CD
MA/NN
patients/NNS
,/,
whereas/IN
no/DT
variation/NN
at/IN
the/DT
same/JJ
SNP/NN
site/NN
was/VBD
found/VBN
in/IN
142/CD
healthy/JJ
male/JJ
controls/NNS
(/(
Table/JJ
2/CD
)/)
./.
====================
Furthermore/RB
,/,
the/DT
resulting/VBG
substitution/NN
was/VBD
probably/RB
damaging/VBG
based/VBN
on/IN
an/DT
in/FW
silico/NN
prediction/NN
of/IN
the/DT
functional/JJ
effect/NN
of/IN
the/DT
nonsynonymous/JJ
SNP/NN
./.
====================
The/DT
biological/JJ
importance/NN
of/IN
the/DT
Leu57Gln/NN
polymorphism/NN
is/VBZ
not/RB
yet/RB
clear/JJ
./.
====================
However/RB
,/,
the/DT
Leu57Gln/NN
substitution/NN
,/,
located/JJ
immediately/RB
adjacent/JJ
to/TO
the/DT
CAGrepeat/NN
,/,
might/MD
be/VB
important/JJ
in/IN
the/DT
biological/JJ
functions/NNS
of/IN
the/DT
AR/NNS
protein/NN
,/,
since/IN
the/DT
glutamine/NN
tracts/NNS
encoded/VBN
by/IN
the/DT
CAGrepeats/NNS
region/NN
in/IN
exon/NN
1/CD
of/IN
the/DT
AR/NNS
gene/NN
are/VBP
involved/VBN
in/IN
receptor/NN
function/NN
and/CC
are/VBP
associated/VBN
with/IN
human/JJ
neurodegenerative/JJ
disease/NN
(/(
Lieberman/JJ
,/,
2008/CD
;/:
Rusmini/NNP
,/,
2010/CD
)/)
./.
====================
However/RB
,/,
variations/NNS
in/IN
two/CD
polymorphic/JJ
trinucleotide/NN
repeat/NN
segments/NNS
that/DT
encode/VBP
polyglutamine/JJ
and/CC
polyglycine/NN
tracts/NNS
of/IN
the/DT
AR/NNS
protein/NN
do/VBP
not/RB
seem/VB
to/TO
directly/RB
contribute/VB
to/TO
the/DT
MA/NN
phenotype/NN
,/,
because/IN
their/PRP$
expansions/NNS
are/VBP
in/IN
the/DT
normal/JJ
range/NN
(/(
∼1528/CD
repeats/NNS
for/IN
CAG/NN
and/CC
∼1218/CD
repeats/NNS
for/IN
GGC/NN
)/)
and/CC
their/PRP$
frequencies/NNS
are/VBP
similar/JJ
to/TO
those/DT
of/IN
control/JJ
groups/NNS
./.
====================
Notably/RB
,/,
whereas/IN
expansion/NN
(/(
≥40/CD
)/)
of/IN
the/DT
CAG/NN
repeat/NN
encoding/VBG
polyglutamine/JJ
tracts/NNS
causes/VBZ
spinal/JJ
bulbar/JJ
muscular/JJ
atrophy/NN
(/(
Kennedy/NN
disease/NN
)/)
(/(
La/NN
Spada/NN
et/FW
al./FW
,/,
1991/CD
)/)
,/,
it/PRP
does/VBZ
not/RB
seem/VB
to/TO
influence/VB
the/DT
development/NN
of/IN
MA/NN
./.
====================
Our/PRP$
study/NN
and/CC
those/DT
of/IN
others/NNS
have/VBP
reported/VBN
a/DT
sexdependent/JJ
prevalence/NN
of/IN
MA/NN
,/,
predominantly/RB
in/IN
males/NNS
(/(
Misra/NN
et/FW
al./FW
,/,
2005/CD
)/)
./.
====================
Thus/RB
,/,
it/PRP
is/VBZ
reasonable/JJ
to/TO
speculate/VB
that/IN
the/DT
high/JJ
prevalence/NN
of/IN
MA/NN
in/IN
males/NNS
may/MD
be/VB
mediated/VBN
by/IN
defects/NNS
in/IN
the/DT
androgen/NN
response/NN
attributable/JJ
to/TO
the/DT
Leu57Gln/NN
substitution/NN
in/IN
the/DT
AR/NNS
protein/NN
,/,
because/IN
mutations/NNS
in/IN
the/DT
AR/NNS
gene/NN
are/VBP
associated/VBN
with/IN
androgen/NN
insensitivity/NN
(/(
McPhaul/NNP
et/FW
al./FW
,/,
1992/CD
)/)
./.
====================
Furthermore/RB
,/,
it/PRP
has/VBZ
been/VBN
reported/VBN
that/IN
expansion/NN
of/IN
the/DT
number/NN
of/IN
glutamine/NN
repeats/NNS
increases/VBZ
neurotoxicity/NN
in/IN
motor/NN
neurons/NNS
of/IN
the/DT
spinal/JJ
cord/NN
(/(
Lee/NNP
et/FW
al./FW
,/,
2003/CD
)/)
./.
====================
Therefore/RB
,/,
the/DT
change/NN
of/IN
leucine/NN
to/TO
glutamine/NN
at/IN
residue/NN
57/CD
of/IN
the/DT
AR/NNS
protein/NN
could/MD
cause/VB
neurotoxicity/NN
in/IN
spinal/JJ
motor/NN
neuronsa/NN
characteristic/JJ
feature/NN
of/IN
MA/NN
./.
====================
We/PRP
also/RB
can/MD
not/RB
exclude/VB
the/DT
possible/JJ
joint/NN
involvement/NN
of/IN
environmental/JJ
factors/NNS
,/,
such/JJ
as/IN
testosterone/NN
or/CC
androgen/NN
effects/NNS
,/,
in/IN
the/DT
development/NN
of/IN
MA/NN
./.
====================
Although/IN
we/PRP
found/VBD
the/DT
Leu57Gln/NN
polymorphism/NN
in/IN
MA/NN
patients/NNS
only/RB
,/,
it/PRP
is/VBZ
premature/JJ
to/TO
conclude/VB
that/IN
the/DT
AR/NNS
gene/NN
is/VBZ
a/DT
causal/JJ
or/CC
susceptibility/NN
gene/NN
for/IN
MA/NN
./.
====================
One/CD
major/JJ
limitation/NN
of/IN
our/PRP$
study/NN
is/VBZ
its/PRP$
small/JJ
sample/NN
size/NN
,/,
a/DT
limitation/NN
inherent/JJ
in/IN
studies/NNS
of/IN
rare/JJ
diseases/NNS
and/CC
one/CD
that/DT
is/VBZ
shared/VBN
by/IN
previous/JJ
genetic/JJ
studies/NNS
of/IN
MA/NN
(/(
Misra/NN
et/FW
al./FW
,/,
2005/CD
;/:
Di/NNP
Guglielmo/NN
et/FW
al./FW
,/,
1996/CD
)/)
./.
====================
Therefore/RB
,/,
further/RBR
studies/NNS
using/VBG
other/JJ
independent/JJ
sample/NN
sets/NNS
are/VBP
necessary/JJ
to/TO
validate/VB
our/PRP$
results/NNS
./.
====================
In/IN
summary/NN
,/,
we/PRP
found/VBD
a/DT
polymorphism/NN
in/IN
the/DT
AR/NNS
gene/NN
encoding/VBG
a/DT
Leu57Gln/NN
variant/JJ
in/IN
MA/NN
patients/NNS
only/RB
./.
====================
However/RB
,/,
no/DT
significant/JJ
changes/NNS
in/IN
polymorphic/JJ
trinucleotide/NN
repeat/NN
segments/NNS
were/VBD
observed/VBN
in/IN
MA/NN
patients/NNS
./.
====================
Our/PRP$
results/NNS
suggest/VBP
that/IN
disruption/NN
of/IN
AR/NNS
protein/NN
function/NN
caused/VBD
by/IN
the/DT
Leu57Gln/NN
substitution/NN
may/MD
play/VB
a/DT
role/NN
in/IN
the/DT
development/NN
of/IN
MA/NN
./.
====================
